S208: EFFICACY AND SAFETY OF ZANDELISIB ADMINISTERED BY INTERMITTENT DOSING (ID) IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) FOLLICULAR LYMPHOMA: PRIMARY ANALYSIS OF THE GLOBAL PHASE 2 STUDY TIDAL. (23rd June 2022) - Zelenetz, A.; Jurczak, W.; Ribrag, V.; Linton, K.; Collins, G.; Lopéz-Jiménez, J.; Reddy, N.; Mengarelli, A.; Phillips, T.; Musuraca, G.; Sheehy, O.; Li, J.; et al.